Alkermes (ALKS) EBIT Margin Growth (3y) (2013 - 2026)
Alkermes (ALKS) EBIT Margin Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 1,129.00 |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | 2.00 |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | 59.00 |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | -1,031.00 |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -925.00 |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | -46.00 |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 6,666.00 |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Alkermes | 8.15 Bn | 7.49 Bn | 397.90 Mn | -4,186.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4,186.00 |
| Mar 31, 2026 | -847.00 |
| Dec 31, 2025 | -2,283.00 |
| Sep 30, 2025 | 191,763.00 |
| Jun 30, 2025 | 110,058.00 |
| Mar 31, 2025 | 1,404.00 |
| Dec 31, 2024 | -205.00 |
| Sep 30, 2024 | 3,439.00 |
| Jun 30, 2024 | 2,607.00 |
| Mar 31, 2024 | 1,890.00 |
| Dec 31, 2023 | 2,545.00 |
| Sep 30, 2023 | 2,744.00 |
| Jun 30, 2023 | 5,916.00 |
| Mar 31, 2023 | 1,136.00 |
| Dec 31, 2022 | 23,662.00 |
| Sep 30, 2022 | -187,402.00 |
| Jun 30, 2022 | -106,395.00 |
| Mar 31, 2022 | 2,452.00 |
| Dec 31, 2021 | 3,984.00 |
| Sep 30, 2021 | 826.00 |